责任编辑：山上 格隆汇12月8日丨鲁抗医药(600789.SH)公布，公司近日获得山东省财政厅关于中央污染防治的政府补助 资金，金额为1436万元，占公司2024年度经审计净利润的3.52%。 股票频道更多独家策划、专家专栏，免费查阅>> ...

Core Viewpoint - Lu Kang Pharmaceutical (600789) has received a government subsidy of 14,360,000.00 yuan, which is expected to positively impact the company's profits for the fiscal year 2025 [1] Financial Performance - As of December 9, 2025, Lu Kang Pharmaceutical's stock closed at 9.52 yuan, down 1.45% from the previous trading day [1] - The stock opened at 9.67 yuan, reached a high of 9.74 yuan, and a low of 9.51 yuan, with a trading volume of 2.56 billion yuan and a turnover rate of 2.97% [1] - The latest total market capitalization of the company is 85.55 billion yuan [1] Government Subsidy - The government subsidy received by Lu Kang Pharmaceutical accounts for 3.52% of the company's audited net profit for the fiscal year 2024 [1] - The subsidy is categorized as an asset-related government grant, which is anticipated to have a positive effect on the company's profits for the fiscal year 2025 [1] - The final accounting treatment and impact on annual profit and loss will be confirmed by the auditing institution [1]

证券代码：600789 证券简称：鲁抗医药 公告编号：2025-053 山东鲁抗医药股份有限公司 特此公告。 山东鲁抗医药股份有限公司董事会 二、补助的类型及其对上市公司的影响 1、补助的类型 根据《企业会计准则第 16 号一一政府补助》的有关规定，此补助资金属于与资产相关的政府补助。 2、对上市公司的影响 此补助预计对公司2025年度的利润产生一定的积极影响。上述政府补助未经审计，具体的会计处理以及 对公司相关年度损益的影响须以审计机构年度审计确认后的结果为准。敬请广大投资者注意投资风险。 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、获得补助的基本情况 山东鲁抗医药股份有限公司（以下简称"公司"）近日获得山东省财政厅关于中央污染防治的政府补助资 金，金额为14,360,000.00 元，占公司2024年度经审计净利润的3.52%。 2025年12月9日 ...

证券日报网讯 12月8日，鲁抗医药（600789）在互动平台回答投资者提问时表示，2025年5月全球首个 乌头酸生物制造项目在鲁抗投产运行，通过合成生物技术，系统构建起了"反式乌头酸微生物绿色制 造"新路线，这一跨越标志着我国率先突破了反式乌头酸量产的技术壁垒，为我国橡塑行业高质量发展 提供了更环保、安全的解决方案。产品凭借"高效增塑、无毒环保"等优势，可广泛应用于特种橡胶、医 用PVC、儿童用品、生物农药等行业。 ...

证券日报网讯 12月8日晚间，鲁抗医药发布公告称，公司近日获得山东省财政厅关于中央污染防治的政 府补助资金，金额为14，360，000.00元。 （文章来源：证券日报） ...

证券日报网讯 12月8日，鲁抗医药在互动平台回答投资者提问时表示，公司持续强化研发投入，不断优 化提升产品结构，打造"两优势六特色"产品管线，全身抗感染产品覆盖抗细菌、抗真菌、抗病毒、抗耐 药菌等多种系列，多个产品市场占有率居于首位，目前系列产品保持产销稳定。 （编辑 姚尧） ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、获得补助的基本情况 山东鲁抗医药股份有限公司（以下简称"公司"）近日获得山东省财政厅关 于中央污染防治的政府补助资金，金额为 14,360,000.00 元，占公司 2024 年度 经审计净利润的 3.52%。 二、补助的类型及其对上市公司的影响 证券代码：600789 证券简称：鲁抗医药 公告编号：2025-053 山东鲁抗医药股份有限公司 关于获得政府补助的公告 2、对上市公司的影响 此补助预计对公司2025年度的利润产生一定的积极影响。上述政府补助未经 审计，具体的会计处理以及对公司相关年度损益的影响须以审计机构年度审计确 认后的结果为准。敬请广大投资者注意投资风险。 特此公告。 山东鲁抗医药股份有限公司董事会 2025 年 12 月 9 日 1、补助的类型 根据《企业会计准则第 16 号——政府补助》的有关规定，此补助资金属于 与资产相关的政府补助。 ...

据鲁抗医药公告，山东鲁抗医药股份有限公司近日获得山东省财政厅关于中央污染防治的政府补助资 金，金额为14,360,000.00元，占公司2024年度经审计净利润的3.52%。 ...

Core Insights - The article emphasizes the growing importance of grassroots healthcare in China's medical system, highlighting its role as the first line of defense for public health [1][4][7] - The number of grassroots healthcare institutions in China is projected to reach 1.04 million by 2024, accounting for 95.10% of all medical institutions in the country [1][4] - The revenue of the grassroots healthcare market is expected to grow to 544.5 billion yuan in 2024, with a forecasted increase to 652.2 billion yuan by 2025 [1][7] Grassroots Healthcare Industry Definition and Classification - Grassroots healthcare refers to the primary level of medical care, primarily outpatient services, and includes community health service centers, township hospitals, village clinics, and other medical facilities [2][3] - It serves as the foundation of the healthcare system, providing accessible, comprehensive, and continuous services to the population [2][3] Current Development Status of Grassroots Healthcare - The number of grassroots healthcare institutions has been increasing, with community health service centers and township hospitals making up a significant portion of the total [4][5] - By 2024, community health service centers will number 37,000, and township hospitals will number 33,000, contributing to the overall growth of the sector [4][5] Industry Revenue and Market Growth - The grassroots healthcare market revenue is projected to increase by 48 billion yuan from 2023 to 2024, reaching 544.5 billion yuan [7] - The community health center drug market is expected to reach 107.4 billion yuan in 2024, while the drug market for township hospitals is projected to be 115.8 billion yuan [7] Industry Chain - The upstream of the grassroots healthcare industry includes medical equipment, pharmaceuticals, medical devices, and third-party service providers, while the midstream consists of healthcare service institutions [7][8] - The downstream targets a wide demographic, particularly focusing on the elderly, chronic disease patients, and children [7][8] Policy Environment - The Chinese government has prioritized health development, implementing policies to enhance the grassroots healthcare system, such as optimizing the layout of healthcare institutions [8][9] Competitive Landscape - The competitive landscape includes both domestic and foreign enterprises, with domestic companies holding a larger market share in grassroots healthcare institutions [11][12] - In 2024, foreign enterprises are expected to account for over 20% of the community health center market, while domestic companies dominate township hospitals with a 92.8% share [11][12] Performance Management Strategies - Strengthening grassroots healthcare service capabilities is a strategic focus to address public health challenges and improve resource allocation [13][14] - High-quality performance management is essential for the long-term development of grassroots healthcare, necessitating continuous improvement and optimization of management strategies [14][15]

济宁高新区合成生物产业发展交流会。 核芯医药企业场景。 生命科学中心提供载体支撑。 于伟通讯员吴丛赵相炎济宁报道 合成生物学是一门前沿学科,也是生物制造产业的创新源头。国家"十五五"规划提出"前瞻布局未来产 业",将生物制造这一未来产业列为新的经济增长点。 作为国家级生物技术产业基地,济宁高新区紧跟国家战略,将合成生物作为医药健康产业重点突破领域,出 政策、引人才、建平台、设基金……正全力竞逐新质生产力新赛道。 1 院士领衔 转化成果高效落地 位于济宁高新区的核芯医药(山东)有限公司(以下简称"核芯医药")的生产车间,正进行DHA藻油产品的试 生产,而该产品正是合成生物产业转化成果落地项目之一。 "我们与南京师范大学黄和院士团队签约合作,作为承接黄院士团队合成生物学研发成果的转化基地,目前 DHA藻油项目已率先落地。"核芯医药常务副总经理袁海滨指着企业园区规划图介绍,"这个车间改造后, 现有四个生物发酵罐,专门用于DHA藻油产品生产,目前已进入到最后的试生产阶段,预计在明年实现量 产,前期产量预计约1000吨,整个立项规模可达到3750吨/年。" DHA藻油,是通过生物合成手段,利用特定菌发酵获得,相比传统鱼 ...